QIAGEN powered by
QCI Interpret 2021 Release Now Available
SEE WHAT'S NEW
QIAGEN Digital Insights
Partner Program
Learn More
Genomic surveillance of SARS-CoV-2 with QIAGEN Digital Insights
LEARN MORE
Previous
Next

40+

integrated databases

90,000+

users worldwide

20M+

curated findings

5,000+

new data findings/day

1,600,000+

patient tests analyzed

Expert curated genomic and clinical knowledge, together with bioinformatics software and services, for actionable insights

Accelerated Decisions

Access over 40 genomic, clinical and pharmaceutical databases updated weekly by hundreds of expert curators.

Deeper Insights

Enrich your NGS analysis and interpretations with cutting-edge bioinformatics software solutions trusted by thousands worldwide.

Better Outcomes

Make improvements in life possible by partnering with one bioinformatics software provider empowering you from Sample to Insight.

Research Bioinformatics Services

Discovery Bioinformatics Services is a reliable and convenient way to extend your in-house resources with expertise and perfectly tailored bioinformatics software and services that ensure high-quality results.

Pharmaceutical Development Services

Enabling pharma companies to develop biomarker diagnostics and targeted therapies using real-world insights from oncology patient genomic data.

Clinical Analysis & Interpretation Services

Helping clinical testing laboratories leverage the benefits of automation and expert support to improve test turnaround times, enhance clinical reporting capabilities and scale for future growth.

Webinars and Events

Join us at an event or attend a webinar to learn how our products, solutions and services are empowering customers around the world to unlock valuable molecular insights.

Case Study 1

Çukurova University in Adana, Turkey, analyzes the ancient origins of rare genetic diseases

Case Study 2

Scientists at the University of Washington develop new Ebola model and find clues to genetics of host resistance

Case Study 3

Mount Sinai identifies a novel prognostic biomarker associated with treatement response in ovarian cancer patients

Log Out